Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


18.04.2017

1 Am J Clin Pathol
2 Ann Oncol
13 Ann Thorac Surg
4 Anticancer Res
1 Arch Bronconeumol
1 BMC Cancer
1 BMJ
1 Chest
1 Clin Cancer Res
1 Eur J Cancer
3 Eur J Cardiothorac Surg
2 Eur Respir J
1 Int J Cancer
1 Int J Oncol
1 J Cancer Res Clin Oncol
3 Lancet
2 Lancet Respir Med
2 Mol Cancer Ther
2 Mol Carcinog
1 Oncogene
6 Oncol Rep
1 Oncologist
6 PLoS One
3 Semin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. SU Y, Goncalves T, Dias-Santagata D, Hoang MP, et al
    Immunohistochemical Detection of ROS1 Fusion.
    Am J Clin Pathol. 2017;147:77-82.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. HARATANI K, Hayashi H, Tanaka T, Kaneda H, et al
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. SEO S, Woo CG, Lee DH, Choi J, et al
    The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small cell lung cancer.
    Ann Oncol. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    


    Ann Thorac Surg

  4. RUSCH VW, Gill R, Mitchell A, Naidich D, et al
    A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
    Ann Thorac Surg. 2016 Sep 2. pii: S0003-4975(16)30785.
    PubMed     Text format     Abstract available

  5. PETRELLA F, Radice D, Casiraghi M, Gasparri R, et al
    Glasgow Prognostic Score Class 2 Predicts Prolonged Intensive Care Unit Stay in Patients Undergoing Pneumonectomy.
    Ann Thorac Surg. 2016;102:1898-1904.
    PubMed     Text format     Abstract available

  6. HANDY JR JR, Costas K, Nisco S, Schaerf R, et al
    Regarding American College of Surgeons Commission on Cancer Non-Small Cell Lung Cancer Quality of Care Measure 10RLN.
    Ann Thorac Surg. 2016;102:1040-1.
    PubMed     Text format    

  7. SINGH G, Coffey A, Neely R, Lambert D, et al
    Pulmonary Kirsten Rat Sarcoma Virus Mutation Positive Mucinous Adenocarcinoma Arising in a Congenital Pulmonary Airway Malformation, Mixed Type 1 and 2.
    Ann Thorac Surg. 2016;102:e335-7.
    PubMed     Text format     Abstract available

  8. VALLABHAJOSYULA S, Blackmon SH
    Left Lower Lobe Pulmonary Torsion.
    Ann Thorac Surg. 2016;102:e361.
    PubMed     Text format    

  9. WATANABE Y, Kusumoto M, Yoshida A, Shiraishi K, et al
    Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator.
    Ann Thorac Surg. 2016;102:1863-1871.
    PubMed     Text format     Abstract available

  10. IKEZAWA Y, Shinagawa N, Sukoh N, Morimoto M, et al
    Usefulness of Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation for Ground-Glass Opacity Lesions.
    Ann Thorac Surg. 2016 Nov 5. pii: S0003-4975(16)31163.
    PubMed     Text format     Abstract available

  11. YANG SM, Wang ML, Hung MH, Hsu HH, et al
    Tubeless Uniportal Thoracoscopic Wedge Resection for Peripheral Lung Nodules.
    Ann Thorac Surg. 2017;103:462-468.
    PubMed     Text format     Abstract available

  12. WANG C, Chen H, Sun L, Mei Y, et al
    Cardiac Cavernous Hemangioma Coexisting With Pulmonary Cavernous Hemangiomas and Giant Hepatic Hemangioma.
    Ann Thorac Surg. 2017;103:e149-e152.
    PubMed     Text format     Abstract available

  13. SCRIMGEOUR LA, Grada Z, Aswad BI, Ng T, et al
    Lessons Learned From an Untreated "Benign" Thoracic Tumor.
    Ann Thorac Surg. 2017;103:e135-e137.
    PubMed     Text format     Abstract available

  14. SONODA D, Mikubo M, Shiomi K, Satoh Y, et al
    Complete Resection of Oligorecurrence of Stage I Lung Adenocarcinoma 19 Years After Operation.
    Ann Thorac Surg. 2017;103:e119-e120.
    PubMed     Text format     Abstract available

  15. ROCCO G
    Invited Commentary.
    Ann Thorac Surg. 2017;103:468-469.
    PubMed     Text format    

  16. D'AMICO TA
    Invited Commentary.
    Ann Thorac Surg. 2017;103:460-461.
    PubMed     Text format    


    Anticancer Res

  17. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Text format     Abstract available

  18. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available

  19. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Text format     Abstract available

  20. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  21. RUANO-RAVINA A, Provencio-Pulla M, Casan Clara P
    Lung Cancer Screening With Low-Dose Computed Tomography is not a Question of Logistics.
    Arch Bronconeumol. 2017 Apr 6. pii: S0300-2896(17)30060.
    PubMed     Text format    


    BMC Cancer

  22. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Text format     Abstract available


    BMJ

  23. WALLACH JD, Sullivan PG, Trepanowski JF, Steyerberg EW, et al
    Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.
    BMJ. 2016;355:i5826.
    PubMed     Text format     Abstract available


    Chest

  24. AVIRAM G, Revel MP
    Misclassification of Lymph Nodes in Lung Cancer Staging: Can We Improve?
    Chest. 2017;151:733-734.
    PubMed     Text format    


    Clin Cancer Res

  25. LI AN, Yang J, Zhang XC, Zhang Z, et al
    Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
    PubMed     Text format     Abstract available


    Eur J Cancer

  26. GIROUX LEPRIEUR E, Dumenil C, Julie C, Giraud V, et al
    Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Eur J Cancer. 2017;78:16-23.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  27. DZIEDZIC R, Zurek W, Marjanski T, Rudzinski P, et al
    Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registrydagger.
    Eur J Cardiothorac Surg. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available

  28. WELTER S, Arfanis E, Christoph D, Hager T, et al
    Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size?dagger.
    Eur J Cardiothorac Surg. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available

  29. ANDERSON KL JR, Mulvihill MS, Yerokun BA, Speicher PJ, et al
    Induction chemotherapy for T3N0M0 non-small-cell lung cancer increases the rate of complete resection but does not confer improved survival.
    Eur J Cardiothorac Surg. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur Respir J

  30. TIAN Q, Deng WJ, Li ZW
    Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  31. KHIROYA H, Moore JS, Ahmad N, Kay J, et al
    IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    Int J Cancer

  32. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Text format     Abstract available


    Int J Oncol

  33. KUMAMOTO T, Seki N, Mataki H, Mizuno K, et al
    Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
    Int J Oncol. 2016;49:1870-1880.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  34. COSTA GJ, de Mello MJ, Ferreira CG, Thuler LC, et al
    Undertreatment trend in elderly lung cancer patients in Brazil.
    J Cancer Res Clin Oncol. 2017 Apr 7. doi: 10.1007/s00432-017-2412.
    PubMed     Text format     Abstract available


    Lancet

  35. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
    Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
    Lancet. 2017;389:1395-1396.
    PubMed     Text format    

  36. CAGNEY DN, Alexander BM, Aizer AA
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1394-1395.
    PubMed     Text format    

  37. ZHU J, Kang M, Fan X
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1395.
    PubMed     Text format    


    Lancet Respir Med

  38. MITSUDOMI T
    Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.
    Lancet Respir Med. 2017 Apr 10. pii: S2213-2600(17)30134.
    PubMed     Text format    

  39. ROSELL R, Dafni U, Felip E, Curioni-Fontecedro A, et al
    Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Lancet Respir Med. 2017 Apr 10. pii: S2213-2600(17)30129.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  40. MANUEL-MANRESA P, Korrodi-Gregorio L, Hernando E, Villanueva A, et al
    Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0752.2016.
    PubMed     Text format     Abstract available

  41. GIMENEZ-XAVIER P, Pros E, Bonastre E, Moran S, et al
    Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0104.2017.
    PubMed     Text format     Abstract available


    Mol Carcinog

  42. ZHANG X, Zhou H, Cai L, Fan C, et al
    Kctd20 promotes the development of non-small cell lung cancer through activating Fak/AKT pathway and predicts poor overall survival of patients.
    Mol Carcinog. 2017 Apr 11. doi: 10.1002/mc.22660.
    PubMed     Text format     Abstract available

  43. XIE M, Wu X, Zhang J, Zhang J, et al
    Ski regulates Smads and TAZ signaling to suppress lung cancer progression.
    Mol Carcinog. 2017 Apr 11. doi: 10.1002/mc.22661.
    PubMed     Text format     Abstract available


    Oncogene

  44. LU W, Cheng F, Yan W, Li X, et al
    Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  45. YAN J, Ma C, Gao Y
    MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines.
    Oncol Rep. 2017;37:3146-3154.
    PubMed     Text format     Abstract available

  46. WANG J, Wang Y, Sun D, Ren F, et al
    CUTL1 induces epithelial-mesenchymal transition in non-small cell lung cancer.
    Oncol Rep. 2017;37:3068-3074.
    PubMed     Text format     Abstract available

  47. CHEN G, Yu H, Satherley L, Zabkiewicz C, et al
    The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer.
    Oncol Rep. 2017;37:2695-2701.
    PubMed     Text format     Abstract available

  48. CAI Y, Ruan J, Yao X, Zhao L, et al
    MicroRNA-187 modulates epithelial-mesenchymal transition by targeting PTRF in non-small cell lung cancer.
    Oncol Rep. 2017;37:2787-2794.
    PubMed     Text format     Abstract available

  49. ZHANG B, Zhang Y, Yu D
    Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery.
    Oncol Rep. 2017;37:937-944.
    PubMed     Text format     Abstract available

  50. LIN D, Kuang G, Wan J, Zhang X, et al
    Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression.
    Oncol Rep. 2017;37:895-902.
    PubMed     Text format     Abstract available


    Oncologist

  51. AGGARWAL C, Borghaei H
    Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
    Oncologist. 2017 Apr 13. pii: theoncologist.2016-0345.
    PubMed     Text format     Abstract available


    PLoS One

  52. SHEN G, Lan Y, Zhang K, Ren P, et al
    Correction: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2017;12:e0176150.
    PubMed     Text format     Abstract available

  53. HE M, Yang Z, Zhang L, Song C, et al
    Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
    PLoS One. 2017;12:e0175466.
    PubMed     Text format     Abstract available

  54. SHIRAI K, Kawashima M, Saitoh JI, Abe T, et al
    Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study.
    PLoS One. 2017;12:e0175589.
    PubMed     Text format     Abstract available

  55. DAVIES J, Patel M, Gridelli C, de Marinis F, et al
    Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.
    PLoS One. 2017;12:e0175679.
    PubMed     Text format     Abstract available

  56. FAN L, Chen L, Ni X, Guo S, et al
    Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population.
    PLoS One. 2017;12:e0175666.
    PubMed     Text format     Abstract available

  57. CAO G, Cheng D, Ye L, Pan Y, et al
    Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences.
    PLoS One. 2017;12:e0175284.
    PubMed     Text format     Abstract available


    Semin Oncol

  58. PINSKY PF
    Commentary on "Screening for lung cancer" by Sateia et al.
    Semin Oncol. 2017;44:83-84.
    PubMed     Text format    

  59. SATEIA HF, Choi Y, Stewart RW, Peairs KS, et al
    Screening for lung cancer.
    Semin Oncol. 2017;44:74-82.
    PubMed     Text format     Abstract available

  60. KAZANDJIAN D, Keegan P, Suzman DL, Pazdur R, et al
    Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.
    Semin Oncol. 2017;44:3-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: